Remarkably similar findings with another SGLT2i in HFrEF - PACE-CME

Remarkably similar findings with another SGLTi in HFrEF

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
ESC 2020
No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
- Prof. Freek Verheugt, MD
Incredible consistency between two SGLT2i trials in HFrEF
Incredible consistency between two SGLT2i trials in HFrEF
ESC 2020
Incredible consistency between two SGLT2i trials in HFrEF
- Milton Packer, MD
BP lowering should be considered irrespective of prior CVD or baseline SBP
BP lowering should be considered irrespective of prior CVD or baseline SBP
ESC 2020
BP lowering should be considered irrespective of prior CVD or baseline SBP
- Kazem Rahimi, MD
Colchicine reduces primary outcome in chronic coronary disease
Colchicine reduces primary outcome in chronic coronary disease
ESC 2020
Colchicine reduces primary outcome in chronic coronary disease
- Mark Nidorf, MD